2026 ICD-10-CM Diagnosis Code Z17.411Hormone receptor positive with human epidermal growth factor receptor 2 negative status

ICD-10-CM Codes›Z00–Z99›Z17›Z17

ICD-10-CM Z17.411
CMSSource: CMS FY 2026 ICD-10-CM dataset · Effective Oct 1, 2025 – Sep 30, 2026

Z17.411 is a billable ICD-10-CM diagnosis code for hormone receptor positive with human epidermal growth factor receptor 2 negative status. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026). The code is not accepted as a principal diagnosis by the Medicare Code Editor and exempt from POA reporting. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Genetic susceptibility to disease.

Code Identity

ICD-10-CM Code
Z17.411
Billable Status
Yes — Valid for Submission
Code Describes
Hormone receptor positive with human epidermal growth factor receptor 2 negative status
Short Description
Hormone recept pos w hmn epdrml grth fctr recept 2 neg stat
Parent Code
Z17.41
Hormone receptor positive

Code Classification

ChapterZ00–Z99Factors influencing health status and contact with health services
SectionZ17Estrogen, and other hormones and factors receptor status
CategoryZ17Estrogen, and other hormones and factors receptor status
This CodeZ17.411Hormone receptor positive with human epidermal growth factor receptor 2 negative status

Code EditsBilling

Medicare Code Editor checks that affect claim validity for Z17.411.

Unacceptable principal diagnosis
There are selected codes that describe a circumstance which influences an individual's health status but not a current illness or injury, or codes that are not specific manifestations but may be due to an underlying cause. These codes are considered unacceptable as a principal diagnosis.

Present on Admission (POA)Billing

Z17.411 is exempt from POA reporting on inpatient claims to general acute care hospitals. Review other POA exempt codes.

Tabular List NotesGuidance

Coding notes and annotation back-references applicable to this code.

Inclusion Terms

  • HR+ with HER2-

Index to Diseases and InjuriesGuidance

Alphabetical index entries that point to this code.

External Cause of Injuries IndexGuidance

References for this code in the External Cause of Injuries Index.

    • Status(post)
      • combined receptor
        • positive
          • hormone receptor positive with human epidermal growth factor receptor 2 negative

Clinical ClassificationClinical

AHRQ’s CCSR groups this code into broader clinical categories.

CCSR FAC029
Genetic susceptibility to disease
Default principal diagnosis: inpatient No · outpatient No

Clinical InformationClinical

  • Advanced Hormone Receptor-Positive Breast Carcinoma|Advanced Hormone Receptor Positive Breast Adenocarcinoma|Advanced Hormone Receptor Positive Breast Carcinoma

    hormone receptor-positive breast carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.

  • FSHR Positive|FSH Receptor Positive|FSH-R Positive|Follicle Stimulating Hormone Receptor Positive|Follicle-Stimulating Hormone Receptor Positive|Follitropin Receptor Positive

    an indication that fshr expression has been detected in a sample.

  • GNRHR Positive|GNRHR1 Positive|GRHR Positive|Gonadotropin Releasing Hormone Receptor Positive|Gonadotropin-Releasing Hormone Receptor Positive|LHRH Receptor Positive|LHRHR Positive|LRHR Positive|Luteinizing Releasing Hormone Receptor Positive|Luteinizing-Releasing Hormone (LHRH) Receptor Positive|Luteinizing-Releasing Hormone Receptor Positive

    an indication that expression of gnrhr has been detected in a sample.

  • Hormone Receptor Positive

    a finding indicating that the neoplastic cells in a breast cancer tissue sample test positive for estrogen or progesterone receptors.

  • Hormone Receptor Positive

    a finding indicating that the neoplastic cells in a tissue sample test positive for hormone receptors.

  • Hormone Receptor-Positive Breast Carcinoma|Hormone Receptor Positive Breast Adenocarcinoma|Hormone Receptor Positive Breast Carcinoma|Hormone Receptor Positive Breast Carcinoma

    breast adenocarcinoma that is positive for hormone receptors.

  • Locally Advanced Hormone Receptor-Positive Breast Carcinoma|Locally Advanced Hormone Receptor Positive Breast Carcinoma

    hormone receptor-positive breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes.

  • Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma|Locally Advanced Unresectable Hormone Receptor Positive Breast Adenocarcinoma|Locally Advanced Unresectable Hormone Receptor Positive Breast Carcinoma|Locally Advanced Unresectable Hormone Receptor-Positive Breast Adenocarcinoma

    hormone receptor-positive breast carcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.

  • Metastatic Hormone Receptor-Positive Breast Carcinoma|Metastatic Hormone Receptor Positive Breast Adenocarcinoma|Metastatic Hormone Receptor Positive Breast Carcinoma

    hormone receptor-positive breast carcinoma that has spread from its original site of growth to another anatomic site.

  • Recurrent Hormone Receptor-Positive Breast Carcinoma|Recurrent Hormone Receptor Positive Breast Adenocarcinoma|Recurrent Hormone Receptor Positive Breast Carcinoma

    the reemergence of hormone receptor-positive breast adenocarcinoma after a period of remission.

  • Refractory Hormone Receptor-Positive Breast Carcinoma|Refractory Hormone Receptor Positive Breast Adenocarcinoma|Refractory Hormone Receptor Positive Breast Carcinoma|Refractory Hormone Receptor Positive Breast Carcinoma

    hormone receptor-positive breast adenocarcinoma that does not respond to treatment.

  • Unresectable Hormone Receptor-Positive Breast Carcinoma|Unresectable Hormone Receptor Positive Breast Adenocarcinoma|Unresectable Hormone Receptor Positive Breast Carcinoma

    hormone receptor-positive breast carcinoma that is not amenable to surgical resection.

  • Advanced Hormone Receptor-Positive Breast Carcinoma|Advanced Hormone Receptor Positive Breast Adenocarcinoma|Advanced Hormone Receptor Positive Breast Carcinoma

    a hormone receptor-positive breast carcinoma that has spread extensively to other anatomic sites or is no longer responding to treatment.

  • Locally Advanced Unresectable Hormone Receptor-Positive Breast Carcinoma|Locally Advanced Unresectable Hormone Receptor Positive Breast Adenocarcinoma|Locally Advanced Unresectable Hormone Receptor Positive Breast Carcinoma|Locally Advanced Unresectable Hormone Receptor-Positive Breast Adenocarcinoma

    hormone receptor-positive breast adenocarcinoma that has spread from its original site of growth to nearby tissues or lymph nodes and is not amenable to surgical resection.

  • Unresectable Hormone Receptor-Positive Breast Carcinoma|Unresectable Hormone Receptor Positive Breast Adenocarcinoma|Unresectable Hormone Receptor Positive Breast Carcinoma

    hormone receptor-positive breast adenocarcinoma that is not amenable to surgical resection.

Code HistoryHistory

FY 2025AddedAdded to the ICD-10-CM code setEffective October 1, 2024.
FY 2026CurrentCurrent code set, no changesEffective October 1, 2025 through September 30, 2026.

Questions About Z17.411Overview

Is Z17.411 (Hormone receptor positive) a billable code?

Yes. This is a billable ICD-10-CM code, specific enough to report hormone receptor positive with human epidermal growth factor receptor 2 negative status on HIPAA-covered claims from October 1, 2025 through September 30, 2026.

Can Z17.411 be a principal diagnosis?

No. The Medicare Code Editor rejects this code as a principal diagnosis because hormone receptor positive with human epidermal growth factor receptor 2 negative status describes a circumstance that influences health status rather than a current illness. Report it as a secondary diagnosis.

Is Z17.411 exempt from POA reporting?

Yes. CMS lists this code among those exempt from present on admission reporting, so hospitals do not assign a POA indicator for hormone receptor positive with human epidermal growth factor receptor 2 negative status on inpatient claims.